Non-viral gene therapy for myocardial engineering.

Area of Science:

• Cardiovascular Research
• Gene Therapy
• Regenerative Medicine

Background:

• Myocardial infarction (MI) is a leading cause of death globally, with current treatments unable to regenerate damaged heart tissue.
• Post-MI, the infarcted myocardium forms scar tissue, leading to impaired cardiac function.
• Cardiac gene therapy aims to minimize damage and promote myocardial regeneration.

Purpose of the Study:

• To review non-viral gene therapy approaches for myocardial regeneration after infarction.
• To discuss the efficacy and challenges of naked plasmid and cell-mediated gene delivery in pre-clinical and clinical cardiac studies.

Main Methods:

• Review of pre-clinical and clinical trial data on non-viral gene delivery to cardiac tissue.
• Focus on naked plasmid delivery (naked or complexed) and genetically modified cell-mediated delivery.
• Exclusion of unmodified stem cells, focusing solely on genetically modified cells for therapeutic gene transfer.

Main Results:

• Viral vectors offer high transfection but pose risks like immunogenicity and insertional mutagenesis.
• Non-viral methods, including naked plasmids and engineered cells, are explored as safer alternatives.
• Limited understanding of unmodified stem cell paracrine effects necessitates focus on genetically modified cells.

Conclusions:

• Non-viral gene therapy presents a promising avenue for myocardial regeneration post-MI.
• Naked plasmid and genetically modified cell delivery warrant further investigation for clinical translation.
• Addressing challenges in gene delivery efficiency and safety is crucial for advancing cardiac repair strategies.